Iannantuoni, F., M. de Marañon, A., Díaz Morales, N., Falcon, R., Bañuls, C., Abad-Jimenez, Z., . . . Rovira-Llopis, S. (2019). The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes.
Citación estilo ChicagoIannantuoni, Francesca, Aranzazu M. de Marañon, Noelia Díaz Morales, Rosa Falcon, Celia Bañuls, Zaida Abad-Jimenez, Victor M. Victor, Antonio Hernandez-Mijares, y Susana Rovira-Llopis. The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes. 2019.
Cita MLAIannantuoni, Francesca, et al. The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes. 2019.